Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Initiation Research Published by Pello Capital

19 Sep 2019 07:00

RNS Number : 8814M
Adamas Finance Asia Limited
19 September 2019
 

RNS REACH

19 September 2019

ADAMAS FINANCE ASIA LIMITED

(the "Company" or "ADAM")

Initiation Research published by Pello Capital

Adamas Finance Asia Limited (AIM: ADAM), the London quoted pan-Asian diversified investment vehicle, is pleased to announce that Pello Capital Limited, the Company's Joint Corporate Broker, has this morning initiated research on ADAM (the "Note").

 

The Note provides a comprehensive introduction to the Company, its focus on investing in pan-Asian small and medium-sized enterprises, its portfolio investments, the Company's commitment to its strategy of providing investors with capital growth and dividend income and the potential opportunities present in ADAM's investable universe.

 

The Note is available to download by visiting the following link:

http://adamasfinance.com/assets/research/pello-capital-initiation-note.pdf

 

For further information, please visit the Company's website at http://adamasfinance.com and follow the Company on Twitter (@AdamasFinance).

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

Adamas Finance Asia Limited

+44 (0) 1825 830587

John Croft

 

WH Ireland Limited - Nominated Adviser

 

+44 (0) 20 7220 1666

James Joyce

James Sinclair Ford

VSA Capital Limited - Joint Corporate Broker 

+44 (0) 20 3005 5000

Andrew Monk

Andrew Raca

Pello Capital Limited - Joint Corporate Broker

+44 (0) 20 3700 2500

Tim Sohal

Maitland/AMO - Communications Advisor

+44 (0) 20 7379 5151

James Benjamin

Peter Hamid

 

About Adamas Finance Asia

ADAM is a London quoted investment company focusing on delivering long-term income and capital growth to shareholders through a diverse portfolio of pan-Asian investments. It is committed to providing for investors attractive uncorrelated returns through a combination of capital growth and dividend income well diversified by national geographies and asset classes from the Asian Small and Medium Enterprise (SME) sector.

 

The Company's investment manager, Harmony Capital, which has a dedicated team with established expertise and broad networks across Asia, is focussed on the strategy of creating income and capital growth for shareholders. Harmony Capital is sourcing predominately private opportunities and continues to create a strong pipeline of income generating assets from potential investments in growth sectors across Asia including healthcare, fintech, hospitality, IT and property.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABVLLFKKFEBBK
Date   Source Headline
24th Oct 201810:24 amRNSNet Asset Value Update
16th Oct 201810:34 amRNSDirector/PDMR Shareholding
13th Sep 20187:00 amRNSInterim Results for Six Months Ended 30 June 2018
17th Aug 201811:43 amRNSResult of AGM
13th Aug 201810:50 amRNSNet Asset Value Update
26th Jul 201812:06 pmRNSNet Asset Value Update
23rd Jul 20189:44 amRNSDisposal of Interest in Global Pharm
11th Jul 201810:38 amRNSResult of General Meeting
28th Jun 20183:50 pmRNSPosting of Annual Report and Accounts
21st Jun 20187:00 amRNSFinal Results for the Year Ended 31 December 2017
21st Jun 20187:00 amRNSAppointment of Broker
15th Jun 20188:36 amRNSDisposal of Interest in Global Pharm & GM Notice
27th Apr 20187:00 amRNSUpdate on Disposal of Interest in Global Pharm
26th Apr 20181:57 pmRNSResult of General Meeting
20th Apr 20188:49 amRNSDirector/PDMR Shareholding
5th Apr 20183:54 pmRNSDisposal and Notice of General Meeting
29th Mar 20187:00 amRNSUpdate on Disposal of Interest in Global Pharm
26th Mar 20184:44 pmRNSIncreased Ownership in HKMH
19th Mar 20187:00 amRNSNew Investment
8th Feb 201812:17 pmRNSUpdate - Net Asset Value
2nd Feb 20188:24 amRNSDirector/PDMR Shareholding
15th Jan 20187:00 amRNSFurther re. Disposal of Interest in Global Pharm
21st Dec 20178:54 amRNSIncrease in Shareholding in Hong Kong Mining
31st Oct 201710:23 amRNSNet Asset Value Update
2nd Oct 20177:00 amRNSAppointment of Director
22nd Sep 20177:00 amRNSInterim Results For Six Months End 30 June 2017
20th Sep 201711:18 amRNSAGM and Share Consolidation
15th Sep 20177:00 amRNSDisposal of Interest in Global Pharm
30th Aug 20174:50 pmRNSProposed Share Consolidation
4th Aug 20173:36 pmRNSUpdate on Global Pharm Convertible Bond
27th Jul 20177:00 amRNSNet Asset Value(s)
20th Jul 20179:43 amRNSDirectorate Change
20th Jul 20179:27 amRNSAnnual General Meeting
3rd Jul 20179:14 amRNSAppointment of Director
29th Jun 201710:45 amRNSFinal Results
22nd Jun 20178:46 amRNSFurther Payment of Proceeds for TTS Disposal
15th Jun 20179:43 amRNSPayment of Proceeds for TTS Project Disposal
25th May 201711:06 amRNSResult of Meeting
2nd May 20177:00 amRNSChange of Investment Manager and Investing Policy
24th Feb 201711:45 amRNSUPDATE ON TTS PROJECT DISPOSAL
8th Feb 20179:26 amRNSUPDATE ON TTS PROJECT DISPOSAL
31st Jan 20177:00 amRNSDistribution from GCCF
23rd Jan 20179:15 amRNSUPDATE: REDEMPTION OF GLOBAL PHARM CONVERTIBLE
13th Jan 20178:15 amRNSUPDATE ON TTS PROJECT DISPOSAL
4th Jan 20179:00 amRNSProposed Disposal
29th Dec 20167:00 amRNSDirector/PDMR Shareholding
22nd Dec 20161:18 pmRNSDirector/PDMR Shareholding
20th Dec 20164:19 pmRNSDirector/PDMR Shareholding
13th Dec 20169:23 amRNSDirector/PDMR Shareholding
6th Dec 201612:34 pmRNSCorrection to Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.